Islay Capital Management LLC Has $432,000 Stock Holdings in The Cigna Group (NYSE:CI)

Islay Capital Management LLC decreased its position in shares of The Cigna Group (NYSE:CI) by 2.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,442 shares of the health services provider’s stock after selling 35 shares during the period. Islay Capital Management LLC’s holdings in The Cigna Group were worth $432,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Roman Butler Fullerton & Co. boosted its position in The Cigna Group by 61.4% in the fourth quarter. Roman Butler Fullerton & Co. now owns 9,307 shares of the health services provider’s stock valued at $2,772,000 after buying an additional 3,539 shares in the last quarter. Ellsworth Advisors LLC acquired a new stake in The Cigna Group in the fourth quarter valued at approximately $4,377,000. Sapient Capital LLC acquired a new stake in The Cigna Group in the fourth quarter valued at approximately $2,811,000. Allspring Global Investments Holdings LLC boosted its position in The Cigna Group by 29.5% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 293,438 shares of the health services provider’s stock valued at $87,870,000 after buying an additional 66,891 shares in the last quarter. Finally, Accurate Wealth Management LLC acquired a new stake in The Cigna Group in the fourth quarter valued at approximately $2,244,000. Institutional investors and hedge funds own 86.99% of the company’s stock.

The Cigna Group Stock Up 0.3 %

Shares of NYSE CI traded up $0.92 during mid-day trading on Tuesday, reaching $357.36. 381,130 shares of the company’s stock traded hands, compared to its average volume of 1,550,803. The stock has a market cap of $104.48 billion, a P/E ratio of 20.49, a PEG ratio of 1.09 and a beta of 0.56. The business has a 50-day simple moving average of $350.19 and a 200 day simple moving average of $318.58. The Cigna Group has a 1-year low of $240.50 and a 1-year high of $365.71. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.67 and a quick ratio of 0.67.

The Cigna Group (NYSE:CI) last issued its quarterly earnings data on Friday, February 2nd. The health services provider reported $6.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.54 by $0.25. The firm had revenue of $51.15 billion during the quarter, compared to analysts’ expectations of $48.91 billion. The Cigna Group had a net margin of 2.64% and a return on equity of 13.59%. The business’s revenue was up 11.8% on a year-over-year basis. During the same period last year, the company earned $4.96 earnings per share. On average, analysts expect that The Cigna Group will post 28.36 EPS for the current fiscal year.

The Cigna Group Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 20th. Investors of record on Tuesday, June 4th will be issued a dividend of $1.40 per share. This represents a $5.60 annualized dividend and a yield of 1.57%. The ex-dividend date is Tuesday, June 4th. The Cigna Group’s dividend payout ratio (DPR) is presently 32.20%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Sanford C. Bernstein upgraded shares of The Cigna Group from a “market perform” rating to an “outperform” rating and raised their target price for the company from $330.00 to $372.00 in a research report on Thursday, January 4th. Barclays assumed coverage on shares of The Cigna Group in a research note on Wednesday, March 6th. They set an “overweight” rating and a $393.00 target price for the company. Wells Fargo & Company lifted their target price on shares of The Cigna Group from $334.00 to $348.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 6th. Oppenheimer reissued an “outperform” rating and set a $360.00 target price on shares of The Cigna Group in a research note on Wednesday, January 17th. Finally, StockNews.com raised shares of The Cigna Group from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 14th. Two research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $362.14.

Insider Buying and Selling

In other The Cigna Group news, CEO David Cordani sold 31,209 shares of the business’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $355.17, for a total value of $11,084,500.53. Following the transaction, the chief executive officer now directly owns 348,054 shares in the company, valued at $123,618,339.18. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, insider Eric P. Palmer sold 1,017 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $335.26, for a total value of $340,959.42. Following the sale, the insider now owns 45,564 shares of the company’s stock, valued at $15,275,786.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO David Cordani sold 31,209 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $355.17, for a total transaction of $11,084,500.53. Following the completion of the sale, the chief executive officer now directly owns 348,054 shares in the company, valued at approximately $123,618,339.18. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 114,144 shares of company stock worth $39,296,330. 0.70% of the stock is owned by insiders.

The Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.